Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV

被引：2
|
作者：
Pratley, Richard E.
Dagogo-Jack, Samuel
Charbonnel, Bernard
Cherney, David
Cosentino, Francesco
Mcguire, Darren K.
Essex, Margaret N.
Jones, Philip L. S.
Liu, Jie
Adamsons, Ingrid A.
Lawrence, David
Shih, Weichung J.
Cannon, Christopher P.
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-791-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
791-P
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Ertugliflozin in older patients with type 2 diabetes: an analysis from VERTIS CV
    Pratley, R. E.
    Cannon, C. P.
    Charbonnel, B.
    Cherney, D. Z. I.
    Cosentino, F.
    McGuire, D. K.
    Shih, W. J.
    Essex, M. N.
    Lawrence, D.
    Jones, P. L. S.
    Liu, J.
    Adamsons, I. A.
    Dagogo-Jack, S.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 30 - 31
  • [2] Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV
    Dagogo-Jack, Samuel
    Frederich, Robert
    Charbonnel, Bernard
    Liu, Jie
    Cannon, Christopher P.
    Shi, Harry
    Mcguire, Darren K.
    Cherney, David
    Cosentino, Francesco
    Shih, Weichung J.
    Masiukiewicz, Urszula
    Gantz, Ira
    Pratley, Richard E.
    [J]. DIABETES, 2021, 70
  • [3] Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV
    Cosentino, F.
    Dagogo-Jack, S.
    Frederich, R.
    Cannon, C. P.
    Cherney, D. Z. I.
    Mancuso, J. P.
    Wynant, W.
    Liu, J.
    Cater, N. B.
    Pratley, R. E.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [4] Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Cherney, David
    Charbonnel, Bernard
    Mcguire, Darren K.
    Cosentino, Francesco
    Shih, Weichung J.
    Liu, Jie
    Frederich, Robert
    Mancuso, James P.
    Raji, Annaswamy
    Gantz, Ira
    [J]. DIABETES, 2021, 70
  • [5] Glycaemic efficacy and safety of ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from VERTIS CV
    Dagogo-Jack, S.
    Pratley, R. E.
    Cherney, D. Z. I.
    Charbonnel, B.
    McGuire, D. K.
    Cosentino, F.
    Shih, W. J.
    Liu, J.
    Frederich, R.
    Mancuso, J. P.
    Raji, A.
    Gantz, I.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 225 - 226
  • [6] Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
    Dagogo-Jack, Samuel
    Frederich, Robert
    Liu, Jie
    Cannon, Christopher P.
    Shi, Harry
    Cherney, David Z., I
    Cosentino, Francesco
    Masiukiewicz, Urszula
    Gantz, Ira
    Pratley, Richard E.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (08): : 2042 - 2051
  • [7] Long-term effects of ertugliflozin (ERTU) on liver enzymes and indices in patients with type 2 diabetes: analyses from VERTIS CV
    Corbin, K. D.
    Dagogo-Jack, S.
    Cannon, C. P.
    Charbonnel, B.
    Cherney, D. Z. I.
    Cosentino, F.
    McGuire, D. K.
    Shih, W. J.
    Frederich, R.
    Liu, J.
    Pong, A.
    Cater, N. B.
    Pratley, R. E.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 218 - 219
  • [8] Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
    Cherney, David Z. I.
    Charbonnel, Bernard
    Cosentino, Francesco
    Dagogo-Jack, Samuel
    McGuire, Darren K.
    Pratley, Richard
    Shih, Weichung J.
    Frederich, Robert
    Maldonado, Mario
    Pong, Annpey
    Cannon, Christopher P.
    [J]. DIABETOLOGIA, 2021, 64 (06) : 1256 - 1267
  • [9] Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
    David Z. I. Cherney
    Bernard Charbonnel
    Francesco Cosentino
    Samuel Dagogo-Jack
    Darren K. McGuire
    Richard Pratley
    Weichung J. Shih
    Robert Frederich
    Mario Maldonado
    Annpey Pong
    Christopher P. Cannon
    [J]. Diabetologia, 2021, 64 : 1256 - 1267
  • [10] Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV
    Cherney, D. Z. I.
    Segar, M.
    Pandey, A.
    Cannon, C. P.
    Cosentino, F.
    Dagogo-Jack, S.
    Pratley, R. E.
    Frederich, R.
    Cater, N. B.
    Maldonado, M.
    Liu, J.
    Liu, C. -C.
    Pong, A.
    McGuire, D. K.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2925 - 2925
12345